New understanding of B cell mutation strategies could have implications for vaccines
A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...
AZoLifeSciences on MSN5mon
Study Uncovers Mechanism Behind B-Cell Maturation in Leukemia
While current therapeutic options include chemotherapy and immunotherapy, this study opens new avenues for novel approaches ...
Zacks Small Cap Research on MSN5d
INAB: Introducing INB-600, A γδ T Cell Engager Platform
INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Multiple Sclerosis News Today10d
Epstein-Barr virus may drive MS by dysregulating certain immune cells
Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says ...
Healio1d
‘Landmark’ B-cell depletion data offer hope to patients with IgG4-related disease
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
CURE1d
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
BioSpace2d
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Targeted Oncology4d
Oncologists Favor CAR T-Cell Therapy for Early Relapsed Myeloma
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...
PharmiWeb2d
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...